Sodium Valproate Alleviates Neurodegeneration in SCA3/MJD via Suppressing Apoptosis and Rescuing the Hypoacetylation Levels of Histone H3 and H4
Authors:
Open Access
- 28 January 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1) , e54792
Abstract
Spinocerebellar ataxia type 3 (SCA3) also known as Machado-Joseph Disease (MJD), is one of nine polyglutamine (polyQ) diseases caused by a CAG-trinucelotide repeat expansion within the coding sequence of the ATXN3 gene. There are no disease-modifying treatments for polyQ diseases. Recent studies suggest that an imbalance in histone acetylation may be a key process leading to transcriptional dysregulation in polyQ diseases. Because of this possible imbalance, the application of histone deacetylase (HDAC) inhibitors may be feasible for the treatment of polyQ diseases. To further explore the therapeutic potential of HDAC inhibitors, we constructed two independent preclinical trials with valproic acid (VPA), a promising therapeutic HDAC inhibitor, in both Drosophila and cell SCA3 models. We demonstrated that prolonged use of VPA at specific dose partly prevented eye depigmentation, alleviated climbing disability, and extended the average lifespan of SCA3/MJD transgenic Drosophila. We found that VPA could both increase the acetylation levels of histone H3 and histone H4 and reduce the early apoptotic rate of cells without inhibiting the aggregation of mutant ataxin-3 proteins in MJDtr-Q68- expressing cells. These results collectively support the premise that VPA is a promising therapeutic agent for the treatment of SCA3 and other polyQ diseases.Keywords
This publication has 42 references indexed in Scilit:
- A broad expression profile of the GMR-GAL4 driver in Drosophila melanogasterGenetics and Molecular Research, 2012
- SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's DiseasePLOS ONE, 2011
- Machado-Joseph Disease: from first descriptions to new perspectivesOrphanet Journal of Rare Diseases, 2011
- Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyondThe Lancet Neurology, 2010
- Association of valproate‐induced teratogenesis with histone deacetylase inhibition in vivoThe FASEB Journal, 2005
- Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein inductionJournal of Neurochemistry, 2004
- Aberrant histone acetylation, altered transcription, and retinal degeneration in aDrosophilamodel of polyglutamine disease are rescued by CREB-binding proteinGenes & Development, 2003
- Extended polyglutamine selectively interacts with caspase-8 and -10 in nuclear aggregatesCell Death & Differentiation, 2001
- Hereditary AtaxiasMayo Clinic Proceedings, 2000
- The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNSJournal of Neurochemistry, 1999